BioCentury | May 10, 2019
Emerging Company Profile

HopeMed: Targeting PRLR for chronic diseases

...companies have disclosed developing PRLR inhibitors for endometriosis or alopecia. Xoma Corp., AbbVie Inc. and Oncolix Inc....
...Companies and Institutions Mentioned AbbVie Inc. (NYSE:ABBV), North Chicago, Ill. Bayer AG (Xetra:BAYN), Leverkusen, Germany Oncolix Inc....
...Targets PRL - Prolactin PRLR - Prolactin receptor Hongjiang Li, Staff Writer BAY 1158061 AbbVie Inc. Bayer AG Hope Medicine Inc. Oncolix Inc. Peking...
BioCentury | Feb 2, 2015
Financial News

Oncolix completes venture financing

Oncolix Inc. , Houston, Texas Business: Cancer Date completed: 2015-01-27 Type: Venture financing Raised: $4.2 million Investors: PoC Capital; Integrium Clinical Research; Texas Emerging Technology Fund; and other investors WIR Staff cancer...
Items per page:
1 - 2 of 2
BioCentury | May 10, 2019
Emerging Company Profile

HopeMed: Targeting PRLR for chronic diseases

...companies have disclosed developing PRLR inhibitors for endometriosis or alopecia. Xoma Corp., AbbVie Inc. and Oncolix Inc....
...Companies and Institutions Mentioned AbbVie Inc. (NYSE:ABBV), North Chicago, Ill. Bayer AG (Xetra:BAYN), Leverkusen, Germany Oncolix Inc....
...Targets PRL - Prolactin PRLR - Prolactin receptor Hongjiang Li, Staff Writer BAY 1158061 AbbVie Inc. Bayer AG Hope Medicine Inc. Oncolix Inc. Peking...
BioCentury | Feb 2, 2015
Financial News

Oncolix completes venture financing

Oncolix Inc. , Houston, Texas Business: Cancer Date completed: 2015-01-27 Type: Venture financing Raised: $4.2 million Investors: PoC Capital; Integrium Clinical Research; Texas Emerging Technology Fund; and other investors WIR Staff cancer...
Items per page:
1 - 2 of 2